Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Explore the Safety and Efficacy of Becotatug Vedotin in Pediatric Patients With EGFR-Positive Relapsed/Refractory or Metastatic Solid Tumors

NCT07584499 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07584499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Explore the Safety and Efficacy of Becotatug Vedotin in Pediatric Patients With EGFR-Positive Relapsed/Refractory or Metastatic Solid Tumors
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Recruiting
Start date
May 30, 2026
Completion date
May 30, 2028
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumors, diffuse intrinsic pontine gliomas, head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m), lymphoepithelial carcinoma, medulloblastoma, nasopharyngeal carcinoma, neuroblastoma, other egfr-positive pediatric solid tumors deemed eligible by the investigator, rhabdomyosarcoma, wilms tumor